Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNCT and Cetuximab for Recurrent Head and Neck Cancer
NCT00927147Phase 2Terminated
- Sponsor
- Boneca Corporation
- Start
- Jun 2009
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Boneca Corporation. Started Jun 2009; status: terminated.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00927147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00927147.